Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 5, 2005, Pages 486-500

  Jacobson, Pamala ^a   Rogosheske, John ^b   Barker, Juliet N ^b   Green, Kathleen ^b   Ng, Juki ^b   Weisdorf, Daniel ^b   Tan, Ye ^b   Long, Janel ^b   Remmel, Rory ^b   Sawchuk, Ronald ^b   McGlave, Philip ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG EFFICACY; DRUG MONITORING; DRUG USE; FEMALE; GRAFT FAILURE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

ADULT; AGED; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG MONITORING; FEMALE; GLUCURONIDES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEUTROPHILS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 28144433004     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.08.009     Document Type: Article

References (48)

1. R. Diaconescu, C.R. Flowers, B. Storer, M.L. Sorror, M.B. Maris, D.G. Maloney Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors Blood 104 2004 1550 1558
2. M.L. Sorror, M.B. Maris, B. Storer, B.M. Sandmaier, R. Diaconescu, C. Flowers Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning influence of pretransplantation comorbidities Blood 104 2004 961 968
3. E.P. Alyea, H.T. Kim, V. Ho, C. Cutler, J. Gribben, D.J. DeAngelo Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age Blood 105 2005 1810 1814
4. R.E. Bullingham, A. Nicholls, M. Hale Pharmacokinetics of mycophenolate mofetil (RS61443) a short review Transplant Proc 28 1996 925 929
5. B. Mojarrabi, P.I. Mackenzie The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid Biochem Biophys Res Commun 238 1997 775 778
6. N. Picard, D. Ratanasavanh, A. Premaud, Y. Le Meur, P. Marquet Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism Drug Metab Dispos 33 2005 139 146
7. L.J. Langman, D.F. LeGatt, R.W. Yatscoff Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity Clin Chem 41 1995 295 299
8. A. Griesmacher, G. Weigel, G. Seebacher, M.M. Muller IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide Clin Chem 43 1997 2312 2317
9. I. Nowak, L.M. Shaw Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity Ther Drug Monit 19 1997 358 360
10. CellCept [package insert] 1998 Roche Laboratories Nutley (NJ)
11. B.A. Atcheson, P.J. Taylor, C.M. Kirkpatrick, S.B. Duffull, D.W. Mudge, P.I. Pillans Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia Ther Drug Monit 26 2004 284 286
12. D.W. Mudge, B.A. Atcheson, P.J. Taylor, P.I. Pillans, D.W. Johnson Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient Ther Drug Monit 26 2004 453 455
13. L.T. Weber, E. Schutz, T. Lamersdorf, M. Shipkova, P.D. Niedmann, M. Oellerich Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy Nephrol Dial Transplant 14 Suppl 4 1999 34 35
14. M.D. Hale, A.J. Nicholls, R.E. Bullingham, R. Hene, A. Hoitsma, J.P. Squifflet The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation Clin Pharmacol Ther 64 1998 672 683
15. L.M. Shaw, M. Korecka, D. DeNofrio, K.L. Brayman Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients Clin Biochem 34 2001 17 22
16. L.T. Weber, M. Shipkova, V.W. Armstrong, N. Wagner, E. Schutz, O. Mehls The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients a report of the German study group on mycophenolate mofetil therapy J Am Soc Nephrol 13 2002 759 768
17. T. van Gelder, L.B. Hilbrands, Y. Vanrenterghem, W. Weimar, J.W. de Fijter, J.P. Squifflet A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 1999 261 266
18. L.M. Shaw, A. Nicholls, M. Hale, V.W. Armstrong, M. Oellerich, R. Yatscoff Therapeutic monitoring of mycophenolic acid. A consensus panel report Clin Biochem 31 1998 317 322
19. L.M. Shaw, B. Kaplan, D. DeNofrio, M. Korecka, K.L. Brayman Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation Ther Drug Monit 22 2000 14 19
20. B. Kaplan, S.A. Gruber, R. Nallamathou, S.M. Katz, L.M. Shaw Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure Transplantation 65 1998 1127 1129
21. M. Bornhauser, U. Schuler, G. Porksen, R. Naumann, G. Geissler, C. Thiede Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation Transplantation 67 1999 499 504
22. M.G. Kiehl, M. Shipkova, N. Basara, I.W. Blau, E. Schutz, V.W. Armstrong Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite Clin Biochem 33 2000 203 208
23. N. Basara, W.I. Blau, M.G. Kiehl, B. Schmetzer, M. Bischoff, D. Kirsten Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients Clin Transplant 14 2000 121 126
24. A. Jenke, U. Renner, M. Richte, J. Freiberg-Richter, U. Platzbecker, A. Helwig Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation Clin Transplant 15 2001 176 184
25. M.B. Maris, D. Niederwieser, B.M. Sandmaier, B. Storer, M. Stuart, D. Maloney HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 102 2003 2021 2030
26. H. Glucksberg, R. Storb, A. Fefer, C.D. Buckner, P.E. Neiman, R.A. Clift Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 18 1974 295 304
27. I. Tsina, F. Chu, K. Hama, M. Kaloostian, Y.L. Tam, T. Tarnowski Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma J Chromatogr B Biomed Appl 675 1996 119 129
28. K.Y. Liang, S.L. Zeger Longitudinal data analysis using generalized linear models Biometrika 73 1986 13 22
29. D.Y. Lin Non-parametric inference for cumulative incidence functions in competing risks studies Stat Med 16 1997 901 910
30. D. Cox Regression models and life tables J R Stat Soc B 34 1972 187 220
31. G.C. Yee, S.G. Self, T.R. McGuire, J. Carlin, J.E. Sanders, H.J. Deeg Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation N Engl J Med 319 1988 65 70
32. P. Martin, N. Bleyzac, G. Souillet, C. Galambrun, Y. Bertrand, P.H. Maire Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors Bone Marrow Transplant 32 2003 777 784
33. R. Ghalie, W.E. Fitzsimmons, A. Weinstein, S. Manson, H. Kaizer Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation Ann Pharmacother 28 1994 379 383
34. G. Filler, N. Lepage, B. Delisle, I. Mai Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients Ther Drug Monit 23 2001 514 519
35. L. Pou, M. Brunet, C. Cantarell, E. Vidal, F. Oppenheimer, V. Monforte Mycophenolic acid plasma concentrations influence of comedication Ther Drug Monit 23 2001 35 38
36. I. Nowak, L.M. Shaw Mycophenolic acid binding to human serum albumin characterization and relation to pharmacodynamics Clin Chem 41 1995 1011 1017
37. R.E. Bullingham, A.J. Nicholls, B.R. Kamm Clinical pharmacokinetics of mycophenolate mofetil Clin Pharmacokinet 34 1998 429 455
38. L.M. Shaw, R. Mick, I. Nowak, M. Korecka, K.L. Brayman Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function J Clin Pharmacol 38 1998 268 275
39. M.H. Ensom, N. Partovi, D. Decarie, R.J. Dumont, G. Fradet, R.D. Levy Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients Ther Drug Monit 24 2002 310 314
40. T. van Gelder, J. Klupp, M.J. Barten, U. Christians, R.E. Morris Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid Ther Drug Monit 23 2001 119 128
41. N.W. Brown, M.M. Aw, G. Mieli-Vergani, A. Dhawan, J.M. Tredger Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients effect of cyclosporine and tacrolimus comedication Ther Drug Monit 24 2002 598 606
42. M. Kobayashi, H. Saitoh, K. Tadano, Y. Takahashi, T. Hirano Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats J Pharmacol Exp Ther 309 2004 1029 1035
43. K. Zucker, A. Tsaroucha, L. Olson, V. Esquenazi, A. Tzakis, J. Miller Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation Ther Drug Monit 21 1999 35 43
44. L.T. Weber, M. Shipkova, T. Lamersdorf, P.D. Niedmann, M. Wiesel, A. Mandelbaum Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients J Am Soc Nephrol 9 1998 1511 1520
45. B. Kaplan, H.U. Meier-Kriesche, G. Friedman, S. Mulgaonkar, S. Gruber, M. Korecka The effect of renal insufficiency on mycophenolic acid protein binding J Clin Pharmacol 39 1999 715 720
46. M.B. Maris, B.M. Sandmaier, B. Storer, J. Shizuru, D. Maloney, E. Agura Unrelated peripheral blood stem cell (PBSC) transplantation using nonmyeloablative conditioning and mycophenolate mofetil (MMF) TID results in high engraftment rates [abstract] Blood 104 2004 503a
47. L.E. Schmidt, A. Rasmussen, M.R. Norrelykke, H.E. Poulsen, B.A. Hansen The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients Liver Transpl 7 2001 739 742
48. O.J. Naderer, R.E. Dupuis, E.L. Heinzen, K. Wiwattanawongsa, M.W. Johnson, P.C. Smith The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil J Clin Pharmacol 45 2005 219 226